• Claudia Mendoza-Pinto, Mario García-Carrasco, Socorro Méndez-Martínez, Pamela Munguía-Realpozo, Ivet Etchegaray-Morales, Gerardo Díaz-Merino, Pamela Soto-Santillán, Marco A Escamilla-Márquez, and Alejandro Ruiz-Arguelles.
• Systemic Autoimmune Diseases Research Unit, High Specialty Medical Unit, Centro Médico Nacional Manuel Ávila Camacho-CIBIOR, Instituto Mexicano del Seguro Social.
• Gac Med Mex. 2021 Jan 1; 157 (6): 594-598.

IntroductionPatients with systemic lupus erythematosus (SLE) have a higher prevalence of insulin resistance (IR) and metabolic syndrome (MetS) than controls.ObjectiveTo evaluate IR in non-diabetic women with SLE by means of biomarkers using high-throughput metabolomic techniques.MethodCross-sectional study in patients with SLE. A metabolomic approach was employed using ultra-high performance liquid chromatography coupled with high-resolution mass spectrometry. MetS was evaluated according to NCEP-ATP III criteria.ResultsSeventy patients with SLE were included, out of whom 45 (64.2%) and 27 (38.5%) had IR and MetS, respectively. Patients with IR had a higher body mass index and hypertension more often than those without IR. Chronic damage and disease activity were not related to IR. A Quantose-IR score ≥ 63 was more common in patients with MetS (81.5 vs. 53.5%; p = 0.02). Quantose-IR score was also correlated with the number of criteria for MetS (r: 0.35; p = 0.003).ConclusionsIn non-diabetic women with SLE, the prevalence of IR based on Quantose-IR score was 64.2%.Copyright: © 2021 Permanyer.

13 keywords...

hide…